Clinical trial
An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Plasmablastic Lymphoma (DALYA Trial)
NCT04915248 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Plasmablastic Lymphoma (DALYA Trial)
- Lead sponsor
- Fondazione Italiana Linfomi - ETS
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 11, 2022
- Completion date
- July 1, 2027
- Enrollment
- 28 (estimated)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.